vs
Apellis Pharmaceuticals, Inc.（APLS）与VIAVI SOLUTIONS INC.（VIAV）财务数据对比。点击上方公司名可切换其他公司
VIAVI SOLUTIONS INC.的季度营收约是Apellis Pharmaceuticals, Inc.的2.0倍（$406.8M vs $199.9M），VIAVI SOLUTIONS INC.净利率更高（1.6% vs -29.5%，领先31.1%），VIAVI SOLUTIONS INC.同比增速更快（42.8% vs -5.9%），过去两年VIAVI SOLUTIONS INC.的营收复合增速更高（27.1% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
VIAVI Solutions前身为JDS Uniphase（JDSU）的一部分，是总部位于美国亚利桑那州钱德勒的网络测试、测量与保障技术企业，主营网络测试和监控设备，同时研发的光学技术可应用于材料质量管控、货币防伪、3D动作传感等多个领域，微软Kinect体感游戏控制器的相关技术也来自该公司。
APLS vs VIAV — 直观对比
营收规模更大
VIAV
是对方的2.0倍
$199.9M
营收增速更快
VIAV
高出48.8%
-5.9%
净利率更高
VIAV
高出31.1%
-29.5%
两年增速更快
VIAV
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $406.8M |
| 净利润 | $-59.0M | $6.4M |
| 毛利率 | — | 57.5% |
| 营业利润率 | -25.6% | 6.1% |
| 净利率 | -29.5% | 1.6% |
| 营收同比 | -5.9% | 42.8% |
| 净利润同比 | -62.2% | -76.1% |
| 每股收益（稀释后） | $-0.40 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSVIAV
| Q1 26 | — | $406.8M | ||
| Q4 25 | $199.9M | $369.3M | ||
| Q3 25 | $458.6M | $299.1M | ||
| Q2 25 | $178.5M | $290.5M | ||
| Q1 25 | $166.8M | $284.8M | ||
| Q4 24 | $212.5M | $270.8M | ||
| Q3 24 | $196.8M | $238.2M | ||
| Q2 24 | $199.7M | $252.0M |
净利润APLSVIAV
| Q1 26 | — | $6.4M | ||
| Q4 25 | $-59.0M | $-48.1M | ||
| Q3 25 | $215.7M | $-21.4M | ||
| Q2 25 | $-42.2M | $8.0M | ||
| Q1 25 | $-92.2M | $19.5M | ||
| Q4 24 | $-36.4M | $9.1M | ||
| Q3 24 | $-57.4M | $-1.8M | ||
| Q2 24 | $-37.7M | $-21.7M |
毛利率APLSVIAV
| Q1 26 | — | 57.5% | ||
| Q4 25 | — | 57.0% | ||
| Q3 25 | — | 56.5% | ||
| Q2 25 | — | 56.3% | ||
| Q1 25 | — | 56.4% | ||
| Q4 24 | — | 59.4% | ||
| Q3 24 | — | 57.1% | ||
| Q2 24 | — | 57.8% |
营业利润率APLSVIAV
| Q1 26 | — | 6.1% | ||
| Q4 25 | -25.6% | 3.1% | ||
| Q3 25 | 48.7% | 2.5% | ||
| Q2 25 | -18.6% | 5.3% | ||
| Q1 25 | -50.0% | 3.0% | ||
| Q4 24 | -12.3% | 8.2% | ||
| Q3 24 | -24.0% | 4.8% | ||
| Q2 24 | -14.7% | -2.3% |
净利率APLSVIAV
| Q1 26 | — | 1.6% | ||
| Q4 25 | -29.5% | -13.0% | ||
| Q3 25 | 47.0% | -7.2% | ||
| Q2 25 | -23.6% | 2.8% | ||
| Q1 25 | -55.3% | 6.8% | ||
| Q4 24 | -17.1% | 3.4% | ||
| Q3 24 | -29.2% | -0.8% | ||
| Q2 24 | -18.9% | -8.6% |
每股收益（稀释后）APLSVIAV
| Q1 26 | — | $0.03 | ||
| Q4 25 | $-0.40 | $-0.21 | ||
| Q3 25 | $1.67 | $-0.10 | ||
| Q2 25 | $-0.33 | $0.03 | ||
| Q1 25 | $-0.74 | $0.09 | ||
| Q4 24 | $-0.30 | $0.04 | ||
| Q3 24 | $-0.46 | $-0.01 | ||
| Q2 24 | $-0.30 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $500.8M |
| 总债务越低越好 | — | $1.1B |
| 股东权益账面价值 | $370.1M | $846.5M |
| 总资产 | $1.1B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 1.28× |
8季度趋势，按日历期对齐
现金及短期投资APLSVIAV
| Q1 26 | — | $500.8M | ||
| Q4 25 | $466.2M | $767.4M | ||
| Q3 25 | $479.2M | $545.6M | ||
| Q2 25 | $370.0M | $425.3M | ||
| Q1 25 | $358.4M | $396.8M | ||
| Q4 24 | $411.3M | $509.4M | ||
| Q3 24 | $396.9M | $493.1M | ||
| Q2 24 | $360.1M | $491.2M |
总债务APLSVIAV
| Q1 26 | — | $1.1B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $640.5M | ||
| Q2 25 | — | $396.3M | ||
| Q1 25 | — | $396.1M | ||
| Q4 24 | — | $639.3M | ||
| Q3 24 | — | $637.6M | ||
| Q2 24 | — | $636.0M |
股东权益APLSVIAV
| Q1 26 | — | $846.5M | ||
| Q4 25 | $370.1M | $834.3M | ||
| Q3 25 | $401.2M | $723.9M | ||
| Q2 25 | $156.3M | $780.2M | ||
| Q1 25 | $164.2M | $728.8M | ||
| Q4 24 | $228.5M | $682.8M | ||
| Q3 24 | $237.1M | $702.1M | ||
| Q2 24 | $264.3M | $681.6M |
总资产APLSVIAV
| Q1 26 | — | $2.5B | ||
| Q4 25 | $1.1B | $2.8B | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $821.4M | $2.0B | ||
| Q1 25 | $807.3M | $1.9B | ||
| Q4 24 | $885.1M | $1.7B | ||
| Q3 24 | $901.9M | $1.7B | ||
| Q2 24 | $904.5M | $1.7B |
负债/权益比APLSVIAV
| Q1 26 | — | 1.28× | ||
| Q4 25 | — | 1.46× | ||
| Q3 25 | — | 0.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | — | 0.91× | ||
| Q2 24 | — | 0.93× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSVIAV
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $42.5M | ||
| Q3 25 | $108.5M | $31.0M | ||
| Q2 25 | $4.4M | $23.8M | ||
| Q1 25 | $-53.4M | $7.8M | ||
| Q4 24 | $19.4M | $44.7M | ||
| Q3 24 | $34.1M | $13.5M | ||
| Q2 24 | $-8.3M | $26.2M |
自由现金流APLSVIAV
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $36.9M | ||
| Q3 25 | $108.3M | $22.5M | ||
| Q2 25 | $4.4M | $18.3M | ||
| Q1 25 | $-53.4M | $1.0M | ||
| Q4 24 | $19.3M | $36.5M | ||
| Q3 24 | — | $6.2M | ||
| Q2 24 | $-8.4M | $22.4M |
自由现金流率APLSVIAV
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 10.0% | ||
| Q3 25 | 23.6% | 7.5% | ||
| Q2 25 | 2.5% | 6.3% | ||
| Q1 25 | -32.0% | 0.4% | ||
| Q4 24 | 9.1% | 13.5% | ||
| Q3 24 | — | 2.6% | ||
| Q2 24 | -4.2% | 8.9% |
资本支出强度APLSVIAV
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 1.5% | ||
| Q3 25 | 0.0% | 2.8% | ||
| Q2 25 | 0.0% | 1.9% | ||
| Q1 25 | 0.0% | 2.4% | ||
| Q4 24 | 0.0% | 3.0% | ||
| Q3 24 | 0.0% | 3.1% | ||
| Q2 24 | 0.0% | 1.5% |
现金转化率APLSVIAV
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | 2.98× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | 4.91× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
VIAV
暂无分部数据
